Adalvo is committed to delivering diversified and competitive assets, supporting our partners in every step of their journey. This is what positions Adalvo for success.
We are pleased to announce the successful progression of Cladribine, which is being developed based on the reference brand Mavenclad (Merck) and is indicated in the treatment of Multiple Sclerosis.
The product sold at around $1064mio globally in 2022, according to IQVIA with a very intensive 3Y-CAGR of 18%.
While we are aware that this is a challenging development with many barriers for competition, we are actively pursuing the possibility of filing an ANDA in the US. In the EU, we aim to be among the first companies to file a generic, marking a significant step toward achieving this goal.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!